Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Key Points: Lenalidomide augments nanoscale rearrangements in cortical actin at the human NK-cell immune synapse. Lenalidomide lowers the threshold for NK-cell activation, allowing activation by low levels of ligands on tumor cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Gandhi, A. K., Kang, J., Havens, C. G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M. F., Thakurta, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12708 · Cited by 619
Self-citationBadoux, X. C., Keating, M. J., Wen, S., Wierda, W. G., O'Brien, S. M., Faderl, S., Sargent, R., Burger, J. A., & Ferrajoli, A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8623 · Cited by 158 · cited 2×
“Lenalidomide in combination with anti-CD20 mAb rituximab is currently in clinical trials for some lymphomas.(34,35) To test whether lenalidomide influencedNK-cell activationby rituximab, lenalidomidetreated pNK cells were incubated on surfaces coated with increasing concentrations of rituximab (0.”
Background
Cited by
Salles, G., Duell, J., González Barca, E., Tournilhac, O., Jurczak, W., Liberati, A. M., Nagy, Z., Obr, A., Gaidano, G., André, M., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30225-4 · Cited by 533
Leonard, J. P., Trneny, M., Izutsu, K., Fowler, N. H., Hong, X., Zhu, J., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00010 · Cited by 434
“Fatigue 38 (22) 2 (1) 33 (18) 1 (1) Pyrexia 37 (21) 1 (1) 27 (15) 3 (2) Leukopenia 36 (20) 12 (7) 17 (9) 3 (2) Upper respiratory tract infection 32 (18) 2 (1) 23 (13) 4 (2)”
Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities
Hu, W., Wang, G., Huang, D., Sui, M., & Xu, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01205 · Cited by 398
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Morschhauser, F., Fowler, N. H., Feugier, P., Bouabdallah, R., Tilly, H., Palomba, M. L., Fruchart, C., Libby, E. N., Casasnovas, R.-O., Flinn, I. W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805104 · Cited by 373
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders
Maskalenko, N. A., Zhigarev, D., & Campbell, K. S. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00413-7 · Cited by 256
Metadata
- Authors
- Lagrue, K., Carisey, A., Morgan, D. J., Chopra, R., & Davis, D. M.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2015-07-02
- Volume
- 126
- Issue
- 1
- Pages
- 50-60
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1591236327
- Cited by
- 132
- References
- 5
- FWCI
- 6.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. https://app.cochat.ai/papers/10.1182/blood-2015-01-625004
- The paper
- Lagrue, K., Carisey, A., Morgan, D. J., Chopra, R., & Davis, D. M. (2015). Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. Blood. https://doi.org/10.1182/blood-2015-01-625004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.